MENU
+Compare
NBIX
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$143.26
Change
+$1.34 (+0.94%)
Capitalization
13.72B

NBIX Neurocrine Biosciences Forecast, Technical & Fundamental Analysis

a product based biopharmaceutical company

NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for NBIX with price predictions
Jan 14, 2025

Aroon Indicator for NBIX shows an upward move is likely

NBIX's Aroon Indicator triggered a bullish signal on January 14, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 263 similar instances where the Aroon Indicator showed a similar pattern. In of the 263 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in of 299 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for NBIX moved out of overbought territory on January 14, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 60 cases where NBIX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for NBIX turned negative on January 14, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NBIX broke above its upper Bollinger Band on January 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NBIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.297) is normal, around the industry mean (58.228). P/E Ratio (57.202) is within average values for comparable stocks, (89.834). Projected Growth (PEG Ratio) (0.464) is also within normal values, averaging (2.877). Dividend Yield (0.000) settles around the average of (0.120) among similar stocks. P/S Ratio (7.564) is also within normal values, averaging (19.449).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
NBIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

NBIX is expected to report earnings to fall 13.26% to $1.57 per share on February 11

Neurocrine Biosciences NBIX Stock Earnings Reports
Q4'24
Est.
$1.57
Q3'24
Beat
by $0.29
Q2'24
Beat
by $0.50
Q1'24
Beat
by $0.13
Q4'23
Beat
by $0.33
The last earnings report on October 30 showed earnings per share of $1.81, beating the estimate of $1.52. With 976.52K shares outstanding, the current market capitalization sits at 13.72B.
A.I. Advisor
published General Information

General Information

a product based biopharmaceutical company

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12780 El Camino Real
Phone
+1 858 617-7600
Employees
1400
Web
https://www.neurocrine.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

NBIX and Stocks

Correlation & Price change

A.I.dvisor tells us that NBIX and AVDL have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBIX and AVDL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
+0.94%
AVDL - NBIX
24%
Poorly correlated
-3.13%
ETON - NBIX
23%
Poorly correlated
+0.91%
ELAN - NBIX
22%
Poorly correlated
+0.08%
PCRX - NBIX
21%
Poorly correlated
+1.36%
SUPN - NBIX
21%
Poorly correlated
-0.34%
More